The use of spectral domain OCT measurements may prove beneficial in determining biomarkers of Alzheimer’s disease, according to findings published in the journal, Ophthalmology.
Victor T.T. Chan , MB, and colleagues conducted a systematic review and meta-analysis to examine SD-OCT measurements in Alzheimer’s disease (AD) and mild cognitive impairment.
“The retina long has been considered a window to study disorders in the central nervous system because it is an extension of the brain embryologically, anatomically and physiologically,” Chan, of the department of ophthalmology and visual sciences and the department of medicine and therapeutics at the Chinese University of Hong Kong, and colleagues wrote. “Extensive loss of retinal ganglion cells and their axons has been reported by histopathologic studies in eyes from AD patients and AD animal models.”
The researchers conducted a search of literature to find studies published prior to December 2017 assessing the association between Alzheimer’s disease, mild cognitive impairment and measurements of SD-OCT measurement.
The measurements included ganglion cell-inner plexiform layer (GC-IPL), ganglion cell complex (GCC), macular volume and choroidal thickness. Retinal nerve fiber layer and macular thickness were also measured.
Chan and colleagues found 30 eligible studies involving 1,257 patients with Alzheimer’s disease, 301 patients with mild cognitive impairment and 1,460 controls.
Patients with Alzheimer’s disease showed a significant difference in GC-IPL thickness and GCC thickness when compared with controls, the researchers wrote. Patients with Alzheimer’s had significant differences in macular volume and macular thickness of all inner and outer sectors when compared with controls.
In patients with Alzheimer’s disease, peripapillary retinal nerve fiber layer and choroidal thickness were found to be thinner. – by Earl Holland Jr.
Disclosure: Chan reported no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.